SAPHRIS 2.5 mg/1 (Asenapine Maleate TABLET) 2.5 mg/1

Saphris 2.5 mg sublingual tablets contain asenapine maleate, used for managing certain mental health conditions. Learn about its uses, effects, and precautions.

Strength

2.5 mg/1

Pack Size

1 CASE in 1 CARTON (0456-2402-10) / 1 BLISTER PACK in 1 CASE / 10 TABLET in 1 BLISTER PACK

Manufacturer / TM Owner

Allergan, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Saphris 2.5 mg sublingual tablets are primarily used to manage symptoms of schizophrenia and bipolar disorder. Asenapine maleate, the active ingredient, is designed to be absorbed under the tongue for effective relief. This medication is often prescribed to help stabilize mood and reduce psychotic symptoms, making it a key component in mental health treatment plans.

Side Effects

Common effects of Saphris 2.5 mg sublingual tablets may include drowsiness, dizziness, and dry mouth. Some users might experience mild headaches or nausea. These effects can vary from person to person and typically subside as the body adjusts to the medication.

Precautions & Warnings

Saphris 2.5 mg sublingual tablets should be handled with care. Store them in a cool, dry place away from direct sunlight. Always follow the prescribed dosage and administration instructions provided by your healthcare professional. Avoid chewing or swallowing the tablet; it should be placed under the tongue to dissolve.

Avoid Interactions

Saphris 2.5 mg sublingual tablets may interact with certain medications, including other mental health drugs and alcohol. It's important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always consult with a healthcare professional before starting or stopping any medication.

Frequently Asked Questions

Saphris 2.5 mg sublingual tablets are used to manage symptoms of schizophrenia and bipolar disorder.

Place the tablet under your tongue and allow it to dissolve without chewing or swallowing.

Common side effects may include drowsiness, dizziness, dry mouth, headaches, and nausea.

It's advisable to avoid alcohol while taking Saphris, as it may increase the risk of side effects.

Store Saphris tablets in a cool, dry place away from direct sunlight and out of reach of children.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.